HPL Pharma Ppt (1)

8/12/2019 HPL Pharma Ppt (1)

1/70

1


2/70

Name Roll no

Samiksha Dike 11

Abdul Samad 01 Furqan Ahmed 13

Dipali Manjucha 27

Javed Khan 17

2

GROUP MEMBERS


3/70

PHARMACEUTICAL INDUSTRY

LUPIN PHARMACEUTICALS

PFIZER PHARMACEUTICALS

1

2

3

TOPICS


4/70

The Pharmaceutical Industry

4


5/70

OVERVIEW

5

Mission

Value


6/70

6

Formulations

Pharmaceuticals

API


7/70

Top Companies in World

7


8/70

8

22,476

26,475

33,547

35,645

37,020

42,813

44,200

45,987

53,324

67,809

0 20,000 40,000 60,000 80,000

Abott laboratories

Astrazenca

Roche

Sanofi

Johnson &johnson

GSK

Bayer

Merck & Co

Novartis

Pfizer

Total Net revenue

Total net revenue in

USD mn


9/70

9


10/70

Evolution of Pharmaceutical Industry

10


11/70

Evolution of Pharmaceutical industry

Market Dominated byForeign Companieswith Little Domestic

Participation

Several DomesticCompanies Starttheir Operations

11

1970-1990

Before 1970 1990-2010

IndianCompanies

launch

operations

in foreign

countries


12/70


13/70

13


14/70

14


15/70

GROWTH

15


16/70

16


17/70

17

SWOTAnalysis

Strengths

WeaknessesOpportunities

Threats


18/70

18

STRENGTHS

Low cost of growingHuman resources in the

Pharmaceutical sector

Significant breadth and

depth of product expertise

Strong Low cost

manufacturing sector


19/70

19

WEAKNESSES

Inadequate R&D infrastructure.

Lack of time driven

regulatory infrastructure.

Poor SME base for high

end manufacture.


20/70

20

OPPURTUNITIES

High growth of domestic market

Low cost good skill destination


21/70

21

THREATS

High entry barriers.

Regulatory and non tariff

barriers.

Increased competition.


22/70

Market Value

Research & Development

22

FUTURE PROSPECTS


23/70

100 per cent FDI in Pharmaceutical sector

Jan Aushadhi Campaign

23

GOVERNMENT INITIATIVES


24/70

24


25/70


26/70

LUPIN PHARMACEUTICALS

26

th


27/70

27

8th

Largest Generics Player

Globally by Market

Capitalisation

3rd

Largest Pharmaceutical

Company in India

5th

Largest & Fastest

Growing Generics

Player in the US by

Prescription.

7thLargest Generics

Player in Japan


28/70

28

VALUES

INTEGRITY

WORKINGTOGETHER

RESPECT

FOR PEOPLE

CUSTOMER

ORIENTATION

ENTREPRENEURSHIP

SUPERIOR

PERFORMANCE


29/70

HISTORY

1968- Lupin commenced business.

1972 -Lupin Laboratories Pvt Ltd was incorporated.

1988 -(LHWRF) was founded by Dr Desh BandhuGupta.

1992 -Won FICCI's award for contribution towardsrural development.

29


30/70

2001 - Only Asian Pharmaceutical company to

receive US FDA approvals

2005 -Maiden Employees Stock Option Plan wasimplemented.

2011 - Lupin Acquires I'rom Pharmaceuticalsthrough its Japanese Subsidiary.

30


31/70

ORGANIZATIONAL STRUCTURE

31

Dr. Deshbandhu Gupta

Mrs.Vinita

GuptaMr.Nilesh

GuptaMr Shakti

ChakrabortyDr.Rajendra

KambhojMr Naresh

GuptaMr. .PaulMcGarty

Dr. KamalSharma


32/70

BUSINESSES

32

BUSINESS MIX


33/70

33

8184 85

88 90

19 16 15

12 10

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

2009 2010 2011 2012 2013

BUSINESS MIX

(% CONTRIBUTION)

FORMULATION API

D ti F l ti ( Milli )


34/70

34

11412

13502

15734

19374

23840

0

5000

10000

15000

20000

25000

30000

2009 2010 2011 2012 2013

Domestic Formulation ( Million)


35/70

35


36/70

36

52%

22%

22%

4%

API Therapeutic Contribution

CardioVascular

Others

Anti TB

Ceps

API PRODUCTS


37/70

37

API PRODUCTS


38/70

RESEARCH & DEVELOPMENT


39/70

39

4119

5301

5940

7708

0

1000

2000

3000

4000

5000

6000

7000

8000

9000

2010 2011 2012 2013

R&D spendings in Million


40/70

40


41/70

UNIQUE FEATURES

41


42/70

FINANCIALS

42

AWARDS & RECOGNITION


43/70

43

AWARDS & RECOGNITION


44/70

Forbes India, Business LeadershipAward,2012.

Ernst & Young Entrepreneur of the Year,2012Awarded to Ms. Vinita Gupta.

Great Place to WorkBest Companies to Workfor, 2012.

44


45/70

45

CORPORATE SOCIAL RESPONSIBILITY


46/70


47/70


48/70

ABOUT THE LEADER

Started his career teaching Chemistry at BITS,Pilani.

Established Lupin Pharmaceuticals in 1968.

Family Man.

Visionary.

48


49/70

49


50/70

50


51/70

51

1st WORLDS LARGEST

PHARMACEUTICAL

COMPANY

4th LARGEST PLAYER

GLOBALLY BY

MARKETCAPITALISATION

NAMED 5THBEST

WEALTH CREATOR IN

AMERICA BY FORTUNE

WORLDS LARGEST

RESEARCH BASED

PHARMACEUTICAL &

BIOMEDICAL COMPANY


52/70

Operates and markets its products in over 150countries worldwide.

About 98,000 employees in over 115 countries

52

ABOUT


53/70

53

PFIZERS CORE VALUES

Integrity Respect for People

Customer/Community Focus

Innovation

Teamwork

Performance

Leadership

Quality

COMPANY GOALS AND


54/70

54

COMPANY GOALS AND

OBJECTIVES

Grow in Emerging Markets.

Find new opportunities for established products.

Instill culture of innovation and continuous

improvement.

Invest in complimentary businesses.


55/70

55

HISTORY

Pfi I Hi t


56/70

56

Pfizer Inc. History

1849- Founded by Charles Pfizer and Charles Erhart in

Brooklyn,NY

1900-Incorporated in New Jersey.

1971- Companys Central Research Division created.

1995- Animal health care segment acquired from SmithKline

Beecham.

2000- Pfizer and Warner Lambert merge.


57/70

2003- Acquired Pharmacia Corporation, creating worlds

largest research based pharmaceutical company

2005- Acquired Vicuron Pharmaceuticals to improve

antiviral development program.

2006- Sold consumer healthcare business to J&J.

2009 -Pfizer acquires Wyeth.

2010 - Pfizer announces a diversified R&D platform

named Pfizer Worldwide Research and Development

57

ORGANISATIONAL


58/70

ORGANISATIONAL

STRUCTURE

58


59/70

BUSINESSES

59


60/70

GLOBAL OPPORTUNITIES

60


61/70

61

U.S.A : Acquiring Strong Productand Expertise .

U.K : Embedded Collaboration in Academia


62/70

62

FRANCE : Focused Research

Partnerships

China: Branded Generics


63/70

63

Japan: Branded Generics

Australia:Innovation in Sterile Injectables

FINANCIALS


64/70

4%4%

5%

5%

16%

32%

34%

SPECIALITY CARE

PRIMARY CARE

EMERGING MARKETS

ESTABLISHEDPRODUCTS

CONSUMERHEALTHCARE

ONCOLOGY

OTHER

BUSINESS UNIT REVENUES

64


65/70

65


66/70

RESEARCH & DEVELOPMENT

66

CORPORATE SOCIAL


67/70

CORPORATE SOCIAL

RESPONSIBILITY

67

LEADERSHIP AT PFIZER


68/70

68

LEADERSHIP AT PFIZER


69/70

69


70/70

CONCLUSION

Date post:	03-Jun-2018
Category:	Documents
Upload:	dipali-manjucha
View:	236 times
Download:	0 times

HPL Pharma Ppt (1)

Documents